NCT06840834 2026-03-16
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
Clinical Trials
64 trialsNCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07234058 2026-02-11
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03007030 2025-11-10
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT04400539 2025-09-25
IMPALA
University Hospital, Lille
Phase 2 Recruiting
NCT06057935 2025-07-22
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT06790082 2025-07-03
FAPI-PM
Aalborg University Hospital
Phase 2 Recruiting
NCT02399371 2025-06-11
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Active not recruiting
NCT05188859 2025-05-31
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT04287829 2024-11-05
PEMMELA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT05660616 2024-08-27
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
Phase 2 Completed
NCT04480372 2024-07-01
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Phase 2 Completed
NCT06416930 2024-05-16
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04300244 2024-02-29
NIPU
Oslo University Hospital
Phase 2 Active not recruiting
NCT05930665 2024-02-21
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Sun Yat-sen University
Phase 2 Recruiting
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT04115111 2023-03-15
Diadem
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02568449 2021-12-09
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01085630 2021-08-18
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03213301 2021-07-14
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
Phase 2 Completed
NCT03786419 2021-05-13
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
Phase 2 Withdrawn
NCT00003508 2021-04-27
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Burzynski Research Institute
Phase 2 Terminated
NCT04713761 2021-01-26
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT02303899 2021-01-22
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT03048474 2021-01-20
INITIATE
The Netherlands Cancer Institute
Phase 2 Completed
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT00024076 2020-08-03
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01112293 2020-04-10
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02194231 2020-01-23
ATREUS
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT00334594 2019-05-15
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Swiss Cancer Institute
Phase 2 Completed
NCT02497508 2017-09-14
NivoMes
The Netherlands Cancer Institute
Phase 2 Completed
NCT00895648 2017-05-04
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
University Health Network, Toronto
Phase 2 Terminated
NCT00996567 2017-02-09
MesoMab
University Hospital, Ghent
Phase 2 Completed
NCT02755675 2016-11-21
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Rigshospitalet, Denmark
Phase 2 Unknown
NCT00165503 2016-09-09
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00509041 2016-08-11
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00004183 2016-07-14
Capecitabine in Treating Patients With Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed